|Dr. Paul A. Wagner Ph.D.||CEO & Chairman||752.5k||N/A||1970|
|Mr. Antony A. Riley CPA||Chief Financial Officer||456k||N/A||1967|
|Dr. Hubert C. Chen M.D.||Pres & Chief Scientific Officer||N/A||N/A||1969|
|Mr. Christopher Roenfeldt||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Steven Ruhl||Chief Technical Officer||N/A||N/A||1957|
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Forte Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.